BridgeBio Pharma founder and CEO Neil Kumar said: "These data, combined with our positive proof-of-concept data in LGMD2i and ADH1 earlier this year, highlight BridgeBio's ability to efficiently prosecute high-value programmes in large areas of unmet need.